Growth often gets discussed in numbers, associating with valuation, revenue, expansion and the like. However, these figures can rarely explain how ...

Needham has decided to maintain its Buy rating of I-MAB (NASDAQ:IMAB) and lower its price target from $72.00 to $41.00. Shares of I-MAB are trading down 15.43% over the last 24 hours, at $6.74 per ...

I-Mab acquires Bridge Health, gaining upstream rights to CLDN18.2 antibody, reducing milestone payments for givastomig and eliminating royalties. I-Mab has announced its acquisition of Bridge Health ...

The long journey from cell culture to a purified monoclonal antibody (mAb) involves many sample processing steps, with clarification and filtration playing significant roles. However, clogs, complex ...

Burnouts are common to many high-powered professionals. But when Christina Mace-Turner suffered a particularly nasty bout of exhaustion she turned to plants and herbal medicine. “I realized there was ...

Malaysia Airlines’ MRO arm, MAB Engineering, is testing new technologies in the hangar and adapting its training strategies to improve maintenance efficiencies. The MRO recently debuted what it calls ...

I-Mab is seeking a partner to jointly develop a cancer drug in the U.S. and Europe as the Chinese firm aims to replicate the success of last year’s $2.9 billion deal with AbbVie Inc., according to ...

Chinese biotechnology firm I-Mab is weighing strategic options as it holds early talks with other global biopharmaceutical companies about partnerships and investments, according to people familiar ...